Taking advantage of drug resistance, a new approach in the war on cancer (Q57172217)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 July 2018

edit

Language	Label	Description	Also known as
English	Taking advantage of drug resistance, a new approach in the war on cancer	scientific article published on 18 July 2018

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

title

Taking advantage of drug resistance, a new approach in the war on cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

author name string

Liqin Wang

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

Rene Bernards

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

language of work or name

English

0 references

publication date

18 July 2018

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

published in

Frontiers of medicine

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

volume

12

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

page(s)

490-495

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

copyright license

Creative Commons Attribution 4.0 International

start time

18 July 2018

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CROSS RESISTANCE AND COLLATERAL SENSITIVITY STUDIES IN CANCER CHEMOTHERAPY.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Critical pathways in cellular senescence and immortalization revealed by gene expression profiling.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular senescence: from physiology to pathology

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent dosing in melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

From Ancient Pathways to Aging Cells-Connecting Metabolism and Cellular Senescence

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent vemurafenib therapy in malignant melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted agents and immunotherapies: optimizing outcomes in melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/30022460

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S11684-018-0647-7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

PubMed publication ID

30022460

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30022460

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30022460%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 April 2020

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57172217&oldid=1893536431"